SCHEMBL24809776

SCHEMBL24809776

COc1nc(C2CCOC2)cn1C(=O)NC1CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.33
PDE10A Q9Y233 2/20 0.33
TYK2 P29597 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
RIPK2 O43353 1/20 0.33
KMT2A Q03164 1/20 0.32
MAPK1 P28482 1/20 0.32
UCHL1 P09936 1/20 0.32
GCK P35557 1/20 0.32
SMO Q99835 1/20 0.32
PIK3CG P48736 1/20 0.31
CSNK1E P49674 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
F2 P00734 1/20 0.31
PLG P00747 1/20 0.31
PLAU P00749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24810730 0.94 SMN1; SMN2 (0.37) SMN1; SMN2KMT2AMAPK1
SCHEMBL24809766 0.86 BCHE (0.34) HPGDSSMN1; SMN2PDE10ACSNK1EPDE4A
SCHEMBL24809790 0.84 MAPT (0.38) SMN1; SMN2KMT2AMAPK1
SCHEMBL24809762 0.81 PDE4D (0.34) SMN1; SMN2IRAK4UCHL1PDE4DNAMPT
SCHEMBL24810569 0.81 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AMAPK1
SCHEMBL24809767 0.79 NAMPT (0.40) NAMPT
SCHEMBL24809411 0.76 CHRM4 (0.40) SMN1; SMN2
SCHEMBL24809418 0.75 CNR2 (0.41) HPGDSSMN1; SMN2IRAK4KMT2AMAPK1
SCHEMBL24810688 0.75 PDCD1LG2 (0.36) HPGDSSMN1; SMN2
SCHEMBL24809773 0.74 PDE10A (0.31) PDE10AF2PLGPLAUPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 US disclosed
EP-4031531-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
CN-114787135-A Substituted imidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, CLN6 HPGDS 1790/4885SMN1; SMN2 79/4885PDE10A 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.